ACTINIUM AC-225 PELGIFATAMAB POPAXETAN
UNII S8KQ6BJU6A

Substance Identification & Data

This profile provides standardized clinical and technical data for Actinium Ac-225 Pelgifatamab Popaxetan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) S8KQ6BJU6A.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3034630-52-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
S8KQ6BJU6A
CAS Registry Number
3034630-52-6
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
ACTINIUM AC-225 PELGIFATAMAB POPAXETAN
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
13693
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Actinium Ac-225 Pelgifatamab Popaxetan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ACTINIUM (225AC) PELGIFATAMAB MOPAXETAN

Common Names & Synonyms

ACTINIUM (225AC) PELGIFATAMAB MOPAXETAN [INN]
ACTINIUM AC-225 PELGIFATAMAB POPAXETAN
H-GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-453) (VH (HOMO SAPIENS IGHV3-33*01 (96.9%) -(IGHD) -IGHJ6*01 (100%), CDR-IMGT (8.8.16) (26-33.51-58.97-112)) (1-123) -HOMO SAPIENS IGHG1*03 (100%), G1M3, NG1M1 (CH1 R120 (220) (124-221), HINGE 1-15 (222-236), CH2 (237-346), CH3 E12 (362), M14 (364) (347-451), CHS (452-453)) (124-453)), (226-214')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-27*01 (94.7%) -IGKJ3*01 (100%), CDR-IMGT (6.3.9) (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (232-232'':235-235'')-BISDISULFIDE, PRODUCED IN A CHINESE HAMSTER OVARY (CHO)-K1 CELL LINE, GLYCOFORM ALFA; CONJUGATED VIA THE SIDE CHAIN NITROGEN OF AN AVERAGE OF 0.8 LYSINE RESIDUES TO ( 225 AC)ACTINIUM RADIOLABELED (4-(2-((2-CARBOXY-6-((16-((6-CARBOXYPYRIDIN-2-YL)METHYL)-1,4,10,13-TETRAOXA-7,16-DIAZACYCLOOCTADECAN-7-YL)METHYL)PYRIDIN-4-YL)OXY)ETHYL)PHENYL)CARBAMOTHIOYL (MOPAXETAN) GROUPS
IMMUNOGLOBULIN G1, ANTI-(HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN) (HUMAN MONOCLONAL TPP-7195 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL TPP-7195 .KAPPA.-CHAIN, DIMER, N6-(((4-(2-((2-(CARBOXY-.KAPPA.O)-6-((16-((6-(CARBOXY-.KAPPA.O)-2-PYRIDINYL-.KAPPA.N)METHYL)-1,4,10,13-TETRAOXA-7,16-DIAZACYCLOOCTADECAN-7-YL-.KAPPA.N7,.KAPPA.N16,.KAPPA.O1,.KAPPA.O4,.KAPPA.O10,.KAPPA.O13)METHYL)-4-PYRIDINYL-.KAPPA.N)OXY)ETHYL)PHENYL)AMINO)THIOXOMETHYL)-L-LYSINE COMPLEX WITH ACTINIUM-225AC
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS FOLH1 (FOLATE HYDROLASE, PROSTATE SPECIFIC MEMBRANE ANTIGEN, PSMA)), HOMO SAPIENS MONOCLONAL ANTIBODY;CONJUGATED TO MOPAXETAN AND RADIOLABELED WITH ACTINIUM-225

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record